The estimated Net Worth of Global Strategic Fund, L.P.... is at least $2.14 millió dollars as of 22 October 2021. Global P owns over 615,702 units of Metacrine stock worth over $1,209,249 and over the last 3 years Global sold MTCR stock worth over $929,710.
Global has made over 1 trades of the Metacrine stock since 2021, according to the Form 4 filled with the SEC. Most recently Global sold 615,702 units of MTCR stock worth $929,710 on 22 October 2021.
The largest trade Global's ever made was selling 615,702 units of Metacrine stock on 22 October 2021 worth over $929,710. On average, Global trades about 615,702 units every 0 days since 2021. As of 22 October 2021 Global still owns at least 2,443,421 units of Metacrine stock.
You can see the complete history of Global P stock trades at the bottom of the page.
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine executives and other stock owners filed with the SEC include: